RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial

• Dana Keilty,

  Affiliation Department of Oncology and Surgery, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada

  ⨯
• Marguerite Buchanan,

  Affiliation Department of Oncology and Surgery, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada

  ⨯
• Katerina Ntapolias,

  Affiliation Department of Pathology, Jewish General Hospital, Montreal, Quebec, Canada

  ⨯
• Olga Aleynikova,

  Affiliation Department of Pathology, Jewish General Hospital, Montreal, Quebec, Canada

  ⨯
• Dongsheng Tu,

  Affiliation NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Ontario, Canada

  ⨯
• Xiao Li,

  Affiliation NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Ontario, Canada

  ⨯
• Lois Shepherd,

  Affiliation NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Ontario, Canada

  ⨯
• Vivien Bramwell,

  Affiliation Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada

  ⨯
• Mark Basik

  * E-mail: markbasik@gmail.com

  Affiliation Department of Oncology and Surgery, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada

  ⨯